Approval of Board for reclassification of Akshath Finvest and Properties Private Limited ,Promoter Group Category into Public Category under Reg 31A of SEBI (LODR)

pdf

Sandu Pharmaceuticals Ltd.

28 May 2025

51.50

2.14%

Result

Sandu Pharmaceuticals Ltd - 524703 - Audited Standalone And Consolidated Financial Results For The Q And …

BSE India

Audited Standalone and consolidated Financial Results for Q and Year Ended 31.03.2025

pdf

Sandu Pharmaceuticals Ltd.

28 May 2025

51.50

2.14%

Board Meeting

Sandu Pharmaceuticals Ltd - 524703 - Board Meeting Outcome for Outcome Of The Board Meeting Dated …

BSE India

Outcome of the Board Meeting

pdf

Sandu Pharmaceuticals Ltd.

24 May 2025

51.50

2.14%

Company Update

Sandu Pharmaceuticals Ltd - 524703 - Announcement Under Regulation 30 Receipt Of Request For Reclassification From …

BSE India

Receipt of the Request from Akshath finvest and Properties Private Limited (Promoter Group) for Reclassification from Promoter category into Public category Under Regulation 31A

pdf

Sandu Pharmaceuticals Ltd.

17 May 2025

51.50

2.14%

Corp. Action

Sandu Pharmaceuticals Ltd - 524703 - Corporate Action-Board to consider Dividend

BSE India

A meeting of the Board of Directors is scheduled to be held on wednesday,28th May 2025 at 03:00pm to consider and recommend final dividend for the year ended 31st March 2025.

pdf

Sandu Pharmaceuticals Ltd.

17 May 2025

51.50

2.14%

Board Meeting

Sandu Pharmaceuticals Ltd - 524703 - Board Meeting Intimation for Approval Of Audited Financial Results For …

BSE India

Sandu Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2025 ,inter alia, to consider and approve Audited Financial Results for Q and year ended 31.03.2025 and to approve Final Dividend if any for the FY ended 31.03.2025

pdf

Sandu Pharmaceuticals Ltd.

21 Apr 2025

51.50

2.14%

Corp. Note

Sandu Pharmaceuticals Ltd - 524703 - Format of the Annual Disclosure to be made by an …

BSE India

Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company Sandu Pharmaceuticals Ltd 2 CIN NO. L24233GA1985PLC001587 3 Report filed for FY 2024-2025 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* NA 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)NA Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-PRATIKA MHAMBRAYDesignation :-COMPANY SECRETARY AND COMPLIANCE OFFICER Name of the Chief Financial Officer :- VIJAY KAJAREKAR Designation : -CHIEF FINANCIAL OFFICER Date: 21/04/2025

pdf

Sandu Pharmaceuticals Ltd.

21 Apr 2025

51.50

2.14%

Corp. Note

Sandu Pharmaceuticals Ltd - 524703 - Format of the Initial Disclosure to be made by an …

BSE India

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanySandu Pharmaceuticals Ltd 2CIN NO.L24233GA1985PLC001587 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY 0 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: PRATIKA MHAMBRAY Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER EmailId: corp.sec@sandu.in Name of the Chief Financial Officer: VIJAY KAJAREKAR Designation: CHIEF FINANCIAL OFFICER EmailId: vijay.k@sandu.in Date: 21/04/2025 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

pdf

Is Sandu Pharmaceuticals Ltd. worth buying?

21 Votes:

Buy 80.95%

Sell 4.76%

Hold 14.29%

25.90% Fall from 52W High

High volume today

Sandu Pharmaceuticals Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Sandu Pharmaceuticals Ltd. on BSE